Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.43 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.43 |
| ▸ | LAP3 | P28838 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FPR1 | P21462 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963548 | 0.84 | CA12 (0.47) | MEN1KMT2ALMNAHSD11B1NPC1 | |
| SCHEMBL964483 | 0.82 | MEN1 (0.44) | MEN1KMT2AALDH1A1HSD11B1NPC1 | |
| SCHEMBL966590 | 0.81 | CA12 (0.49) | MEN1KMT2AALDH1A1HSD11B1NPC1 | |
| SCHEMBL963555 | 0.80 | HSD11B1 (0.46) | MEN1KMT2ALMNAALDH1A1HSD11B1 | |
| SCHEMBL963199 | 0.80 | GAA (0.46) | MEN1KMT2ALMNAPKMALDH1A1 | |
| SCHEMBL966298 | 0.80 | CA12 (0.50) | L3MBTL1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL963233 | 0.74 | MEN1 (0.44) | MEN1KMT2ALMNAHSD11B1NPC1 | |
| SCHEMBL963552 | 0.74 | MEN1 (0.46) | MEN1KMT2ALMNAHSD11B1NPC1 | |
| SCHEMBL4602434 | 0.73 | LMNA (0.50) | L3MBTL1MEN1KMT2ALMNAPKM | |
| SCHEMBL964699 | 0.72 | GBA1 (0.50) | MEN1KMT2AALDH1A1HSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | L3MBTL1 3858/4885MEN1 4766/4885KMT2A 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.